This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Compass Therapeutics’s 8K filing here.
About Compass Therapeutics
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Stories
- Five stocks we like better than Compass Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Airline Stocks – Top Airline Stocks to Buy Now
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
- What Does a Stock Split Mean?
- Tesla’s Closes in on $400: From Laggard to Leader in 2024
